Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Net Sales

Net Sales %Chg

Net Sales Common Size

Cost of Goods Sold

Cost of Goods Sold %Chg

Cost of Goods Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Sales and Distribution Costs

Sales and Distribution Costs %Chg

Sales and Distribution Costs Common Size

Research and Development Costs

Research and Development Costs %Chg

Research and Development Costs Common Size

Administrative Costs

Administrative Costs %Chg

Administrative Costs Common Size

Other Operating Income and Expenses

Other Operating Income and Expenses %Chg

Other Operating Income and Expenses Common Size

Non-Recurring Income from the Initial Public Offering of NNIT a/S

Non-Recurring Income from the Initial Public Offering of NNIT a/S %Chg

Non-Recurring Income from the Initial Public Offering of NNIT a/S Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Financial Income

Financial Income %Chg

Financial Income Common Size

Financial Expenses

Financial Expenses %Chg

Financial Expenses Common Size

Profit Before Income Taxes

Profit Before Income Taxes %Chg

Profit Before Income Taxes Common Size

Income Taxes

Income Taxes %Chg

Income Taxes Common Size

Net Profit

Net Profit %Chg

Net Profit Common Size

Basic Earnings per Share

Basic Earnings per Share %Chg

Basic Earnings per Share Common Size

Diluted Earnings per Share

Diluted Earnings per Share %Chg

Diluted Earnings per Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	74,976	76,857	78,087	85,683	71,311	68,060
Total Revenues %Chg	5.1%	12.9%	19.5%	30.1%	21.4%	25.3%
Net Sales
Cost of Sales	17,904	12,846	12,890	13,024	11,308	10,274
Cost of Goods Sold
Gross Profit	57,072	64,011	65,197	72,659	60,003	57,786
Gross Profit
Gross Profit Margin	76.1%	83.3%	83.5%	84.8%	84.1%	84.9%
Selling, General & Administrative Expenses	17,880	18,849	16,112	20,281	16,592	16,091
Sales and Distribution Costs
Administrative Costs
Research & Development Expenses	15,393	11,690	10,308	13,802	9,488	16,166
Research and Development Costs
Other Operating Expenses	117	23	-14	1,839	101	-405
Other Operating Income and Expenses
Non-Recurring Income from the Initial Public Offering of NNIT a/S
Operating Profit	23,682	33,449	38,791	36,737	33,822	25,934
Operating Profit
Operating Margin	31.6%	43.5%	49.7%	42.9%	47.4%	38.1%
Interest and Investment Income	307	5,314	3,425	3,913	-821	960
Financial Income
Interest Expense	1,528	-4,958	-5,183	-5,093	1,383	-1,562
Financial Expenses
Total Non-Operating Income	1,835	356	-1,758	-1,180	562	-602
Income Before Provision for Income Taxes	25,517	33,805	37,033	35,557	34,384	25,332
Profit Before Income Taxes
Provision for Income Taxes	5,511	7,302	7,999	7,327	7,083	5,282
Income Taxes
Consolidated Net Income	20,006	26,503	29,034	28,230	27,301	20,050
Net Profit
Net Income Attributable to Common Shareholders	20,006	26,503	29,034	28,230	27,301	20,050
Net Profit
Basic EPS	4.5	6	6.5	6.3	6.1	4.5
Diluted EPS	4.5	6	6.5	6.3	6.1	4.5
Basic Weighted Average Shares Outstanding	4,443.5	4,446.8	4,439.4	4,452.7	4,453.7	4,455.6
Total Shares Outstanding	4,439.6	4,439.6	4,439.6	4,465	4,451.4	4,453.9
Diluted Weighted Average Shares Outstanding	4,446.8	4,446.8	4,446.2	4,452.7	4,460.9	4,465.5
EBITDA	31,439	38,282	42,621	41,935	35,972	34,779
Effective Tax Rate	21.6%	21.6%	21.6%	20.6%	20.6%	20.9%